JavaScript is off. Please enable to view full site.

Moderna gets further $472 million U.S. award for coronavirus vaccine development

Moderna gets further $472 million U.S. award for coronavirus vaccine development

Monday, July 27, 2020, 10:32 GMT+7
Moderna gets further $472 million U.S. award for coronavirus vaccine development
A sign marks the headquarters of Moderna Inc, which is developing a vaccine against the coronavirus, in Cambridge, Massachusetts, U.S., May 18, 2020. Photo: Reuters

Moderna Inc said on Sunday it has received an additional $472 million from the U.S. government’s Biomedical Advanced Research and Development Authority (BARDA) to support development of its novel coronavirus vaccine.

The U.S.-based drug maker said the additional funding will support its late-stage clinical development including the expanded Phase 3 study of Moderna’s vaccine candidate. 

In April, Moderna had received $483 million from the U.S. federal agency that funds disease-fighting technology, when the experimental vaccine was in an early-stage trial conducted by the U.S. National Institutes of Health. 

“Encouraged by the Phase 1 data, we believe that our mRNA vaccine may aid in addressing the COVID-19 pandemic and preventing future outbreaks,” Chief Executive Officer Stéphane Bancel said in a press release. 

BARDA’s total funding for the experimental vaccine of Moderna, the first in the United States to begin human trials of a coronavirus vaccine, is now about $955 million. 

The vaccine uses synthetic messenger RNA (mRNA) to inoculate against the coronavirus.

Such treatments help the body immunize against a virus and can potentially be developed and manufactured more quickly than traditional vaccines. 

A Phase 3 study, conducted in collaboration with the National Institute of Allergy and Infectious Diseases, will begin on July 27 and involve about 30,000 participants, according to the company. 

Moderna said it remains on track to be able to deliver about 500 million doses per year, and possibly up to 1 billion doses per year, beginning in 2021. 

The announcement about further funding came two days after the drug developer said its formula used in developing the vaccine was not covered under patents owned by Arbutus Biopharma 

Pfizer Inc, Novavax Inc, Britian’s AstraZeneca Plc are other few drug makers that received funding from BARDA for coronavirus vaccine development.

Reuters

More

Read more

Google unveils latest AI model, Gemini 2.0

Google on Wednesday announced the launch of Gemini 2.0, its most advanced artificial intelligence model to date, as the world's tech giants race to take the lead in the fast developing technology

6 hours ago
;

VIDEOS

‘Taste of Australia’ gala dinner held in Ho Chi Minh City after 2-year hiatus

Taste of Australia Gala Reception has returned to the Park Hyatt Hotel in Ho Chi Minh City's District 1 after a two-year hiatus due to the COVID-19 pandemic

Vietnamese woman gives unconditional love to hundreds of adopted children

Despite her own immense hardship, she has taken in and cared for hundreds of orphans over the past three decades.

Latest news

Google unveils latest AI model, Gemini 2.0

Google on Wednesday announced the launch of Gemini 2.0, its most advanced artificial intelligence model to date, as the world's tech giants race to take the lead in the fast developing technology